Rubicon Genomics announced its new MethylPlex cancer detection system as the “most sensitive method” to find patterns of abnormal DNA methylation in the serum and urine of patients during tumor formation and progression, the company said in a statement. The system produces “high resolution” maps of methylation for “more than 10,000 genes in one day for less than $.10 per gene,” the company added.
The Oncotype Dx Recurrence Score Assay may both predict the risk of breast cancer recurrence and prove useful in identifying women who will benefit most from chemotherapy, said test developers the US National Cancer Institute National Surgical Adjuvant Breast and Bowel Project and Genomic Health this week in a statement. The groups’ results suggest that “almost half” of the more than 50,000 women diagnosed with estrogen-dependent, lymph-node negative breast cancer every year have a low recurrence risk and may not need to undergo chemotherap, the groups said.
US Labs last week launched a new methodology using gene expression profiling for classifying tumors of unknown origin, the company said in a statement. The test has an “86 percent accuracy” rate in clinical studies, the company said.
Web Enabled DNA Testing allows a distant American College of Medical Genetics-certified pathologist to interpret DNA testing results through an interactive Internet portal, said developer Access Genetics in a statement last week.